Do Helper T Cell Subtypes in Lymphocytic Thyroiditis Play a Role in the Antitumor Effect?

Overview

Journal J Pathol Transl Med

Specialty Biomedical Engineering

Date 2016 Sep 30

PMID 27681413

Citations 2

Authors

Seok Woo Yang

Seong-Ho Kang

Kyung Rae Kim

In Hong Choi

Hang Seok Chang

Young Lyun Oh

Soon Won Hong

Affiliations

Soon will be listed here.

Abstract

Background: Papillary thyroid carcinoma (PTC) is frequently accompanied by lymphocytic thyroiditis (LT). Some reports claim that Hashimoto's thyroiditis (the clinical form of LT) enhances the likelihood of PTC; however, others suggest that LT has antitumor activity. This study was aimed to find out the relationship between the patterns of helper T cell (Th) cytokines in thyroid tissue of PTC with or without LT and the clinicopathological manifestation of PTC.

Methods: Fresh surgical samples of PTC with (13 cases) or without (10 cases) LT were used. The prognostic parameters (tumor size, extra-thyroidal extension of PTC, and lymph node metastasis) were analyzed. The mRNA levels of two subtypes of Th cytokines, Th1 (tumor necrosis factor α [TNF-α], interferon γ [IFN-γ ], and interleukin [IL] 2) and Th2 (IL-4 and IL-10), were analyzed. Because most PTC cases were microcarcinomas and recent cases without clinical follow-up, negative or faint p27 immunoreactivity was used as a surrogate marker for lymph node metastasis.

Results: PTC with LT cases showed significantly higher expression of TNF-α (p = .043), IFN-γ (p < .010), IL-4 (p = .015) than those without LT cases. Although the data were not statistically significant, all analyzed cytokines (except for IL-4) were highly expressed in the cases with higher expression of p27 surrogate marker.

Conclusions: These results indicate that mixed Th1 (TNF-α, IFN-γ , and IL-2) and Th2 (IL-10) immunity might play a role in the antitumor effect in terms of lymph node metastasis.

Citing Articles

Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis.

Tang Q, Pan W, Peng L PLoS One. 2022; 17(6):e0269995.

PMID: 35709179 PMC: 9202927. DOI: 10.1371/journal.pone.0269995.

Obesity and Thyroid Cancer Risk: An Update.

Franchini F, Palatucci G, Colao A, Ungaro P, Macchia P, Nettore I Int J Environ Res Public Health. 2022; 19(3).

PMID: 35162142 PMC: 8834607. DOI: 10.3390/ijerph19031116.

References

Yoon Y, Kim H, Lee J, Kim J, Koo B . The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis. Eur Arch Otorhinolaryngol. 2011; 269(3):1013-7. DOI: 10.1007/s00405-011-1732-6. View

Mitsiades C, Poulaki V, Mitsiades N . The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J Endocrinol. 2003; 178(2):205-16. DOI: 10.1677/joe.0.1780205. View

Khoo M, Beasley N, Ezzat S, Freeman J, Asa S . Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002; 87(4):1814-8. DOI: 10.1210/jcem.87.4.8353. View

Yip I, Pang X, Berg L, Hershman J . Antitumor actions of interferon-gamma and interleukin-1 beta on human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1995; 80(5):1664-9. DOI: 10.1210/jcem.80.5.7745015. View

Sobrinho-Simoes M, Preto A, Rocha A, Castro P, Maximo V, Fonseca E . Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 2005; 447(5):787-93. DOI: 10.1007/s00428-005-0065-5. View

Lee J, Kim S . The function of p27 KIP1 during tumor development. Exp Mol Med. 2009; 41(11):765-71. PMC: 2788730. DOI: 10.3858/emm.2009.41.11.102. View

Finke L, Wentworth K, Blumenstein B, Rudolph N, Levitsky H, Hoos A . Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 2007; 25 Suppl 2:B97-B109. DOI: 10.1016/j.vaccine.2007.06.067. View

Vella V, Mineo R, Frasca F, Mazzon E, Pandini G, Vigneri R . Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. J Clin Endocrinol Metab. 2004; 89(6):2880-9. DOI: 10.1210/jc.2003-031639. View

Ahn D, Heo S, Park J, Kim J, Sohn J, Park J . Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol. 2011; 50(8):1228-34. DOI: 10.3109/0284186X.2011.602109. View

10.

Singh B, Shaha A, Trivedi H, Carew J, Poluri A, Shah J . Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999; 126(6):1070-6; discussion 1076-7. DOI: 10.1067/msy.2099.101431. View

11.

Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R . Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol. 2005; 26(2):57-64. DOI: 10.1159/000085586. View

12.

Laurberg P, Nohr S, Pedersen K, Hreidarsson A, Andersen S, Bulow Pedersen I . Thyroid disorders in mild iodine deficiency. Thyroid. 2000; 10(11):951-63. DOI: 10.1089/thy.2000.10.951. View

13.

Mardente S, Lenti L, Lococo E, Consorti F, Della Rocca C, Romeo S . Phenotypic and functional characterization of lymphocytes in autoimmune thyroiditis and in papillary carcinoma. Anticancer Res. 2005; 25(3c):2483-8. View

14.

Ajjan R, Watson P, McIntosh R, Weetman A . Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol. 1996; 105(3):523-8. PMC: 2200538. DOI: 10.1046/j.1365-2249.1996.d01-784.x. View

15.

Larrea M, Liang J, da Silva T, Hong F, Shao S, Han K . Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol. 2008; 28(20):6462-72. PMC: 2577417. DOI: 10.1128/MCB.02300-07. View

16.

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

17.

Paulson L, Shindo M, Schuff K . Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma. Otolaryngol Head Neck Surg. 2012; 147(3):444-9. DOI: 10.1177/0194599812445727. View

18.

Boi F, Lai M, Marziani B, Minerba L, Faa G, Mariotti S . High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol. 2005; 153(5):637-42. DOI: 10.1530/eje.1.02020. View

19.

Karlidag T, Cobanoglu B, Keles E, Alpay H, Ozercan I, Kaygusuz I . Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol. 2006; 28(1):31-6. DOI: 10.1016/j.amjoto.2006.06.008. View

20.

Kebebew E, Weng J, Bauer J, Ranvier G, Clark O, Duh Q . The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246(3):466-70. PMC: 1959359. DOI: 10.1097/SLA.0b013e318148563d. View